Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study

International Journal of Environmental Research and Public Health

Rachele Fornari¹  Edoardo Mocini¹  Andrea Lenzi¹  Giovanni Iolascon²  Giovanna Zimatore³  Chiara Marocco³  Silvia Migliaccio³  VivianaMaria Bimonte³  MariaChiara Gallotta⁴  Carlo Baldari⁵ 

[1] Department of Experimental Medicine, Medical Pathophysiology, Endocrinology and Nutrition Section, University Sapienza of Rome, 00185 Rome, Italy;Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy;Department of Movement, Human and Health Sciences, Health Sciences Section, University Foro Italico of Rome, 00135 Rome, Italy;Department of Physiology and Pharmacology "Vittorio Erspamer”, Sapienza University of Rome, 00185 Rome, Italy;Department of Theoretical and Applied Sciences, eCampus University, 22060 Novedrate, Italy;

关键词: osteoporosis;    anti-resorptive drugs;    therapeutic adherence;    bone mineral density;    biochemical markers;    serum parathyroid hormone;   

DOI  :  10.3390/ijerph18041728

来源: DOAJ

【 摘 要 】

Denosumab is a human monoclonal antibody that neutralizes RANKL, a cytokine able to interact with the RANK receptor on preosteoclasts and osteoclasts, decreasing their recruitment and differentiation, leading to a decreased bone resorption. The aim of this observational real-life study was to analyze adherence to denosumab therapy and assess its efficacy in increasing bone mineral density (BMD) and modulating biochemical skeletal markers following previous treatments with bisphosphonates in a group of post-menopausal women with osteoporosis. Women were recruited in the specialized center from March 2012 to September 2019. Biochemical markers were recorded at baseline and every six months prior to subsequent drug injection. Dual X-ray absorptiometry was requested at baseline and after 18/24 months. Comparing BMD at baseline and after denosumab therapy in naive patients and in those previously treated with bisphosphonates, a positive therapeutic effect was observed in both groups. The results of our real-life study demonstrate, as expected, that BMD values significantly increased upon denosumab treatment. Interestingly, denosumab showed an increased efficacy in patients previously treated with bisphosphonates. Moreover, biochemical markers data indicate that osteoporotic patients, without other concomitant unstable health conditions, could be evaluated once a year, decreasing the number of specialistic center access.

【 授权许可】

Unknown